Resource Summary Report

Generated by nidm-terms on Sep 5, 2026

B6.Cg-Thy1^{a}/Cy Tg(TcraTcrb)8Rest/J

RRID:IMSR_JAX:005023
Type: Organism

Proper Citation

RRID:IMSR_JAX:005023

Organism Information

URL: https://www.jax.org/strain/005023

Proper Citation: RRID:IMSR_JAX:005023

Description: Mus musculus with name B6.Cg-Thy1^{a}/Cy Tg(TcraTcrb)8Rest/J from IMSR.

Species: Mus musculus

Synonyms: B6.Cg Thy1-Tg(TcraTcrb)8Rest/J. pmel-1. C57BL/6-Tg(TcraTcrb)8Rest/J

Notes: gene symbol note: thymus cell antigen 1; theta|T cell receptor beta chain|transgene insertion 8; Nicholas Restifo|T cell receptor alpha chain; mutant strain|congenic strain: Thy1|Tcrb|Tg(TcraTcrb)8Rest|Tcra

Affected Gene: thymus cell antigen 1; theta|T cell receptor beta chain|transgene insertion 8; Nicholas Restifo|T cell receptor alpha chain

Genomic Alteration: a variant|transgene insertion 8; Nicholas Restifo

Catalog Number: JAX:005023

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: live

Organism Name: B6.Cg-Thy1^{a}/Cy Tg(TcraTcrb)8Rest/J

Record Creation Time: 20250513T053647+0000

Record Last Update: 20260905T044429+0000

Ratings and Alerts

No rating or validation information has been found for B6.Cg-Thy1^{a}/Cy Tg(TcraTcrb)8Rest/J.

No alerts have been found for B6.Cg-Thy1^{a}/Cy Tg(TcraTcrb)8Rest/J.

Data and Source Information

Source: Integrated Animals

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 94 mentions in open access literature.

Listed below are recent publications. The full list is available at nidm-terms .

Morgado-Cáceres P, et al. (2026) DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 + T cell responses and therapeutic protection in mouse tumor models. Oncoimmunology, 15(1), 2606497.

Salazar-Cavazos E, et al. (2026) Stochasticity in cancer immunotherapy stems from rare but functionally critical Spark T cells. Cell, 189(4), 1074.

Fu J, et al. (2026) mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy. Cell reports. Medicine, 7(4), 102706.

Hammons JN, et al. (2026) Tumor site influences efficacy of MEKi and immunotherapy combinations in a preclinical model of cholangiocarcinoma. Hepatology (Baltimore, Md.), 84(1), 20.

Jiang H, et al. (2026) IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy. Immunity, 59(1), 177.

Wittling MC, et al. (2026) T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy. Cancer immunology research, 14(3), 463.

Magno JC, et al. (2026) Engineering T Cells with a Tumor-Reactive Chimeric T-cell Receptor Reduces Exhaustion and Promotes Persistence to Elicit Enhanced Antitumor Responses. Cancer research, 86(11), 2688.

Seishima N, et al. (2025) Enhancing DC cancer vaccine by allogeneic MHC class II expression and Treg depletion. JCI insight, 10(16).

Pretto S, et al. (2025) A functional single-cell metabolic survey identifies Elovl1 as a target to enhance CD8+ T cell fitness in solid tumours. Nature metabolism, 7(3), 508.

Zhang R, et al. (2025) USP30 inhibition augments mitophagy to prevent T cell exhaustion. Science advances, 11(33), eadv6902.

Ando Y, et al. (2025) Hyperdifferentiated murine melanoma cells promote adaptive anti-tumor immunity but activate the immune checkpoint system. Oncoimmunology, 14(1), 2437211.

Frisch AT, et al. (2025) Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior T cells for cancer immunotherapy. Cell metabolism, 37(4), 870.

Labiano S, et al. (2025) Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas. Cell reports. Medicine, 6(7), 102204.

Phelps CM, et al. (2025) Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy. Cell.

Srivastava J, et al. (2025) Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors. Cancer research, 85(12), 2268.

Zuo Y, et al. (2025) IL-36? armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunity. Cancer cell.

Cole AC, et al. (2025) Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity. Cancer cell, 43(9), 1697.

Gong L, et al. (2025) Cancer immunology data engine reveals secreted AOAH as a potential immunotherapy. Cell, 188(18), 5062.

Zhang FQ, et al. (2025) Zeaxanthin augments CD8+ effector T cell function and immunotherapy efficacy. Cell reports. Medicine, 6(9), 102324.

Zhou X, et al. (2025) Potentiating anti-tumor immunity by re-engaging immune synapse molecules. Cell reports. Medicine, 6(3), 101975.